BIIB Biogen Inc.
Price Chart
Executive Summary
Biogen has acquired exclusive rights to felzartamab in the Greater China Region from TJ Biopharma, consolidating full global rights to the CD38-directed antibody. The deal includes a $100 million upfront payment and up to $750 million in potential milestone payments, plus tiered royalties on future sales in China.
Key Financial Metrics
Actionable Insight
This deal removes geographic fragmentation and unlocks full global optionality for felzartamab, which is in late-stage trials for multiple high-unmet-need immune diseases. Given China's large patient pool for IgAN and PMN, the market opportunity is substantial. Monitor upcoming Phase 3 readouts as key catalysts for valuation expansion.
Key Facts
- Biogen acquires exclusive Greater China rights to felzartamab from TJ Biopharma
- Total potential deal value: up to $850 million ($100M upfront, $750M in milestones)
- Biogen now holds full worldwide rights to felzartamab, a potential pipeline-in-a-product for immune-mediated diseases
- Felzartamab is in global Phase 3 trials for IgA nephropathy (IgAN), primary membranous nephropathy (PMN), and kidney transplant rejection
- China has one of the largest patient populations globally for IgAN and PMN, representing a major commercial opportunity
- Biogen will lead development, manufacturing, and commercialization in China; TJ Bio to manufacture for multiple myeloma indication
Financial Impact
$100 million upfront expense in Q2 2026; potential additional $750 million in milestone payments tied to commercial success
Risk Factors
- Felzartamab remains investigational with no regulatory approvals yet; clinical trial results may not meet endpoints
- Milestone payments are contingent on commercial success, which depends on regulatory approval and market adoption
- Increased R&D expense from upfront $100M charge may pressure near-term earnings
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276893 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 8, 2026
4d ago
|
ANALYST-UPGRADE
| $194.60 awaiting T+1 | awaiting T+1 | — | $200.05 (+2.80%) |
|
Jun 4, 2026
9d ago
|
Press Release
| $195.82 $195.30 | ▼ −0.27% | ▲ +2.33% | $200.05 (+2.16%) |
|
Jun 1, 2026
12d ago
|
Press Release
| $192.22 $188.66 | ▼ −1.85% | ▼ −2.00% | $200.05 (+4.08%) |
|
May 31, 2026
12d ago
|
ANALYST-UPGRADE
| $156.63 $154.99 | ▼ −1.05% | ▼ −1.18% | $200.05 (+27.72%) |
|
May 22, 2026
21d ago
|
ANALYST-UPGRADE
| $190.12 $187.84 | ▼ −1.20% | ▼ −0.81% | $200.05 (+5.22%) |
|
May 21, 2026
22d ago
|
Press Release
| $193.85 $193.07 | ▲ +0.40% | ▲ +0.99% | $200.05 (−3.20%) |
|
May 20, 2026
23d ago
|
ANALYST-UPGRADE
| $183.33 $185.18 | ▲ +1.01% | ▲ +1.66% | $200.05 (+9.12%) |
|
May 14, 2026
29d ago
|
ANALYST-UPGRADE
| $178.76 $180.47 | ▲ +0.96% | ▲ +0.18% | $200.05 (+11.91%) |
|
May 14, 2026
4w ago
|
Press Release
| $191.26 $192.32 | ▲ +0.55% | ▲ +1.78% | $200.05 (+4.60%) |
|
May 14, 2026
4w ago
|
8-K
| $191.26 $192.32 | ▲ +0.55% | ▲ +1.78% | $200.05 (+4.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access